Article info
PDFResearch ethics
Paper
Terminating clinical trials without sufficient subjects
- Correspondence to Lianne Damen, Commissie Mensgebonden Onderzoek, Research Ethics Committee, PO Box 9101, Internal Code 578, 6500 HB, Nijmegen, The Netherlands; l.damen{at}iwkv.umcn.nl
Citation
Terminating clinical trials without sufficient subjects
Publication history
- Received May 31, 2011
- Revised January 26, 2012
- Accepted January 30, 2012
- First published February 28, 2012.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- Non-completion and informed consent
- Importance and role of independent data monitoring committees (IDMCs) in oncology clinical trials
- Changes in benzodiazepine use in the French general population after November 2015 terrorist attacks in Paris: an interrupted time series analysis of the national CONSTANCES cohort
- How to strengthen clinical research in Shenzhen, China: qualitative study
- Clinical Research From Proposal to Implementation
- Ethics in a scientific approach: the importance of the biostatistician in research ethics committees
- Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines
- Protocol for a systematic literature review and network meta-analysis of the clinical benefit of inhaled maintenance therapies in chronic obstructive pulmonary disease
- Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
- Awareness and enforcement of guidelines for publishing industry-sponsored medical research among publication professionals: the Global Publication Survey